Annales d'Endocrinologie 2013-02-01

Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.

Salha Fendri, Pelin Karaca, Evelyne Tiev, Michael Buchfelder, Jean-Daniel Lalau

Index: Ann. Endocrinol. (Paris.) 74(1) , 49-52, (2013)

Full Text: HTML

Abstract

We report on a 30-year-old female acromegalic patient treated with the growth hormone (GH) receptor antagonist pegvisomant at a low dose after the failure of long-acting lanreotide, neurosurgery and radiotherapy treatment to restore IGF-1 levels. The combination treatment was well tolerated and produced a dramatic improvement in the patient's condition (reduction in visual field defects, relief of headache and excessive perspiration), normalization of IGF-I levels and a considerable decrease in tumor size, enabling a dramatic decrease in lanreotide dosage and, ultimately, its withdrawal.Copyright © 2012 Elsevier Masson SAS. All rights reserved.